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ABSTRACT The interactive association between T lym-
phocytes and their target cells is an important system of
cell-cell interactions. Major histocompatibility complex class I
molecules are the cell surface structures recognized by cytolytic
T lymphocytes. To define the molecular structures recognized
by cytotoxic T lymphocytes, we have saturated the 270-base-
pair al exon of the H-2DP gene with point mutations, rapidly
producing a "library" of 2.5 x 103 independent mutants. The
library contains enough recombinant clones (each clone encod-
ing approximately one amino acid replacement mutation) to
predict a mutation at each nucleotide position of the al exon.
The functional analysis of the first five transfected gene
products tested has shown that mutation of a conserved
tyrosine at position 27 to asparagine destroys recognition of the
H-2DP gene product by polyclonal alloreactive cytotoxic T
lymphocytes. Recognition of the same mutant molecule by
three monoclonal antibodies and H-2-restricted lymphocytic
choriomenengitis virus-specific cytotoxic T lymphocytes is
unaffected.
Mutagenesis has been a useful tool for understanding both
gene function and regulation. Some biological systems have
allowed the production and selection of a large number of
point mutations that approaches saturation of a gene. Classic
examples are the definition of the bacteriophage T4 rII region
(1) and the estimation of the white locus gene size of
Drosophila (2). The generation of a similar spectrum of
mutants in mammalian genes, however, is severely limited by
diploidy, genome complexity, and lack of suitable selection
schemes. Automated DNA synthesis has allowed the rapid in
vitro generation of point mutant libraries that contain all the
possible single-base substitutions of a small defined "target"
sequence (3, 4). We have applied this strategy to the much
larger coding sequence target of a major histocompatibility
complex (MHC) class I gene for a detailed structure-function
analysis. The application of other conventional mutagenesis
approaches requires stringent selection to find mutations that
occur at a rate of 1O-4 to 10-6. Our synthetic approach
ensures that mutations are recovered at a rate of at least 25%
with a controllable frequency per clone. This changes the
major obstacle in mutagenesis experiments from the produc-
tion of mutants to the detailed characterization of systems
with mutant phenotypes. We believe the spectrum of mutants
created by saturation techniques allows for sampling muta-
tions that would not have been easily recovered by other
conventional mutagenesis procedures.
Cytotoxic T lymphocytes (CTLs) recognize epitopes on
syngeneic class I molecules when the class I molecule is
associated with antigen (5). Peptide fragments may associate
with the class I molecule at the cell surface (6), as do MHC
class II molecules and antigen (7, 8), and form the basis of
recognition by CTLs. CTLs also recognize foreign class I
molecules directly (9, 10).
Our laboratory has identified the class I H-2DP gene from
a genomic library by transfection experiments (11). Sequence
analysis revealed a typical murine class I gene (12). Also, we
have shown that most of the H-2DP epitopes recognized by
CTLs and B cells reside in the al and a2 protein domains
(refs. 13 and 14; T. Kanda and J.A.F., unpublished obser-
vations), similar to other murine class I molecules (15-17).
One difficulty in defining important amino acid residues in the
class I molecule is the extreme polymorphism and large size
of the class I molecules. This makes site-directed mutagen-
esis cumbersome, as it is difficult to decide which amino acid
to change. We now report the saturation of an entire exon
with various point mutations at a defined frequency per
clone. The functionally important mutation we describe
(tyrosine-27 to asparagine) provides an insight into the
recognition of class I molecules by alloreactive and self-
restricted CTLs.
MATERIALS AND METHODS
Materials. All restriction endonucleases and DNA ligase
were purchased from New England Biolabs.
Bacterial Strains and Plasmids. Escherichia coli JM107 was
used as a host for phage M13 cloning and propagation of
sequencing templates. E. coli HB101 was used as a host for
all other recombinant DNA work. M13mpl9 was used for
DNA sequencing.
Synthesis of Mutant Oligonucleotides. Twelve oligonucleo-
tides, which collectively comprise synthetic H-2DP al exons,
were synthesized on an Applied Biosystems (Foster City,
CA) DNA synthesizer (3) and purified by polyacrylamide gel
electrophoresis. A 1% equimolar solution of all four nucle-
otide precursors was added to each homogeneous nucleotide
precursor reservoir before synthesis. Thus, as synthesis of
each oligonucleotide proceeded, an incorrect base was ran-
domly incorporated into the oligonucleotide at a frequency
defined by the various concentrations of nucleotide precur-
sors in each reservoir. At each position, there was an equal
probability of incorporating an incorrect base, thus generat-
ing a point mutation.
Assembly of Mutant Oligonucleotides into a1 Restriction
Fragments. Oligonucleotides that had a 5' internal end, in
relation to the final double-stranded structure, were phos-
phorylated. All 12 oligonucleotides were mixed in equimolar
amounts in an Eppendorf tube and placed in 1 liter of boiling
water. The water was allowed to cool to room temperature,
during which time the oligonucleotides annealed to form
Abbreviations: MHC, major histocompatibility complex; CTL, cy-
tolytic T lymphocyte; mAb, monoclonal antibody(ies); LCMV,
lymphocytic choriomenengitis virus.
*To whom reprint requests should be addressed.
3535
The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked "advertisement"
in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Proc. Natl. Acad. Sci. USA 85 (1988)
discrete synthetic mutant restriction fragments. This double-
stranded DNA was ligated and purified on an 8% acrylamide
gel. The ends of the synthetic fragments had been designed
to have Kpn I and Sph I restriction site overhangs at the 5'
and 3' ends, respectively. The structure of the synthetic
mutant exons is shown in Fig. 1. These restriction fragments
were ligated into the Kpn I and Sph I sites of M13mpl9, and
individual clones were sequenced by the dideoxy method as
described (18, 19).
Reconstruction of H-2DP Mutant Genes. Each identified al
mutant sequence has been recloned back into the remainder
of the wild-type H-2DP gene sequence, replacing the wild-
type al exon. The plasmid pRM15 contains a genomic copy
of the H-2DP gene in pUC13. A small portion of intron 3 (Xba
I-BamHI) was removed during construction. A unique Kpn
I restriction site was placed 45 bp on the 5' side of the al
coding sequence by ligation ofa Kpn I linker into a Sma I site.
A unique Sph I restriction site was placed 13 bp on the 3' side
of the al coding sequence, by ligation of an Sph I linker into
a Sma I site. The al exon can be removed from pRM15 by
a Kpn I-Sph I digest. Mutant al exons, purified from M13
replicative forms, were then used to reconstruct intact
mutant H-2DP genes by using standard recombinant DNA
techniques.
Transfection ofH-2DP Mutant Genes into Mouse Ltk- Cells.
Ten micrograms of mutant DNA was linearized with EcoRI.
One microgram of pMT-113/ - 85, which carries the thymi-
dine kinase (tk) gene under control of the metallothionine
promoter (20), was linearized with Xho I. The DNA was
mixed with 107 Ltk - cells and exposed to an electric field of
2000 V/cm at 25 ,F with a time constant of 0.7 msec by using
a Bio-Rad Gene Pulser. The mixture was placed on ice for 10
min, and tk-positive colonies were selected in HAT medium
(with 0.1 mM ZnSO4) as described (11, 20).
RIA of Transfected L Cells. RIA of transfected cells was
performed as described (11). The three H-2DP-specific mono-
clonal antibodies (mAb; 7-16.10, 135, and 11-20.3) used in this
study have been described (21, 22).
CTL Analysis of Transfected Cells. Primary polyclonal
alloreactive CTLs were produced from C3H mice as de-
scribed (23). Spleen cells from C3H mice were cultured for 5
days with irradiated stimulator spleen cells from B10.P mice
and assayed by 51Cr release from the L-cell targets. Lym-
phocytic choriomenengitis virus (LCMV)-specific CTLs
were generated in vivo by infectiQn of B10.P mice with 105
plaque-forming units of Armstrong strain LCMV as de-
scribed (24) and assayed by 51Cr release on day 6 by using
LCMV-infected and uninfected L-cell targets.
RESULTS
Production of the H-2DP al Mutant Library. To produce a













12 oligonucleotides were synthesized under unbiased muta-
genic conditions. The 12,oligonucleotides were then assem-
bled into synthetic mutant al restriction fragments. The
mutant al fragments were directionally cloned into
M13mpl9. Individual recombinants from the library of mu-
tants were sequenced. Thus far 51 of 120 recombinant clones
sequenced retained the correct al reading frame. Thirteen of
the 51 clones were wild type, as predicted by a Poisson
distribution. Thirty-eight clones contained randomly distrib-
uted al point mutations. As expected, these mutations result
in amino acid substitutions, silent mutations, and an occa-
sional stop codon. Thirty of the 38 clones encode amino acid
substitutions that alter the amino acid sequence of the al
protein domain and are candidates for phenotype analysis.
Thus the recovery rate for potentially useful mutations was
25% (30 of 120 mutants), and experiments have shown (R.M.
and J.A.F., unpublished observations) that the recovery rate
can be much higher. The positions of the amino acid substi-
tutions in these 30 clones are shown in Fig. 2. The 30
mutations described here collectively represent 44 amino
acid substitutions in the 90 amino acid al protein sequence,
a domain known to be critical for CTL recognition. Twenty-
five ofthese positions have been substituted once, 6 positions
have been substituted twice, 1 position has been substituted
three times, and 1 position has been substituted four times.
To visualize the distribution of al mutations on the protein
structure, we have noted the positions of the amino acids
substituted: on the al and a2 ribbon structure proposed by
Bjorkman et al. (25) (Fig. 3). We estimate, based on our
sequence analysis sampling, that 2500 individual potentially
useful al mutations exist in the mutant library. Since the al
coding sequence contains 270 bp and 3 nucleotide substitu-
tions are possible at each position, there are 810 total
single-base-change mutants possible (270 positions x 3
substitutions). We expect we have cloned molecules con-
taining at least one mutation at each nucleotide position.
Transfection and Functional Analysis. For clarity, mutants
are designated by their clone number (as shown in Fig. 2)
followed by the wild-type amino acid residue (in the one-
letter amino acid code), the position of the residue, and the
mutant amino acid at that position. Thus, DP20(Y27N) is a
mutant that changes tyrosine-27 to asparagine. Mutant genes
have been transfected, along with the tk gene, into mouse
Ltk- cells, and their products have been expressed on the
cell surface. Table 1 summarizes the data from five mutant
H-2DP class I molecules. These five mutants have been
examined for their ability to (i) bind three DP-specific mAb;
(it) be recognized by polyclonal CTLs specific for DP and
LCMV; and (iii) be recognized by polyclonal alloreactive
CTLs. Four mutants, DP181(D37H), DP164(R14L), DP14-
(AllV;E32Q), and DP174(P57Q), express a mutant molecule
that we cannot functionally distinguish from a wild-type DP
FIG. 1. Structure of the synthetic dou-
ble-stranded mutant al exons assembled
from 12 oligonucleotides. Coding and
noncoding strands were synthesized un-
der unbiased mutagenic conditions and
annealed into discrete restriction frag-
ments to form mutant al "cassettes."
The coding sequence is 270 base pairs
(bp) and is shown between the asterisks
(*). The underlined and boldfaced nucle-
otide positions represent the borders of
each oligonucleotide. Note the overlap of
the coding and noncoding oligonucleo-
tides. The 5' end retained a Kpn I restric-
tion site overhang. The 3' end retained an
Sph I restriction site overhang.
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FIG. 2. Deduced amino acid sequences of wild-type and mutant al domain of DP. The wild-type sequence is shown on the top line in the
single-letter amino acid code. Mutant clone numbers are shown on the left. A dash indicates where the residue in the synthetic sequence is
identical to the wild type. Deduced amino acid substitutions are shown at the appropriate positions. The distribution of mutations is random
throughout the target sequence (j = 3.809; 3 degrees of freedom; P > 0.7).
molecule. We therefore present in detail only the data for the
analysis of DP20(Y27N). L cells expressing this mutant
molecule fail to be recognized by DP-specific alloreactive
CTLs.
Recognition of Mutant Molecules by DP-Specific mAb. Fig.
4 shows representative data from RIA analysis of DP20-
(Y27N). Three DP mAb (7-16.10, 135, and 11-20.3) bind the
FIG. 3. The positions ofthe H-2DP mutations are displayed on the
HLA.A2 ribbon structure redrawn from Bjorkman et al. (25). The
shaded area represents the a2 structure that was not a target for
mutagenesis. The al protein structure is shown with large circles
marking the amino acid positions that we have functionally analyzed.
The distribution of mutations produced by our rapid mutagenesis
technique, but not yet functionally characterized, are shown by the
small circles.
mutant molecule as well as the wild-type molecule. These
antibodies were chosen because they recognize three distinct
epitopes on the DP molecule (ref. 26 and T. Kanda and J.A.F.,
unpublished observations). All other mutants listed in Table
1 also bind these mAb as well as cells expressing a wild-type
DP molecule. We conclude these mutants show no significant
epitope variations detectable with the three mAb used. Also,
these data show comparable expression levels between
Table 1. Summary of CTL recognition of mutant DP molecules
mAb H-2-restricted Allo-
Cell line A B C recognition recognition
WT + + + + +
Ltk+ - - - - -
DP14(A11V; E32Q) + + + + +
DP20(Y27N) + + + + -
DP164(R14L) + + + + +
DP181(D37H) + + + + +
DP174(P57Q) + + + + NT
Summary of the functional analyses ofL cells transfected with five
H-2DP mutant genes, L cells transfected with the wild-type H-2DP
gene (WT), and L cells transfected with only the tk gene (Ltk').
Reactivity with three mAb (A, B, and C) correspond to those listed
in Fig. 4. H-2-restricted recognition of all seven cell types by
polyclonal DP-restricted LCMV-specific CTLs and by polyclonal
C3H DP-allospecific CTL is shown. The wild-type cells are referred
to as + for all the DP-specific reagents (mAb and CTLs). The Ltk+
cells are referred to as - for all the DP-specific reagents. For the
mutants, + indicates that recognition is statistically indistinguish-
able from the wild-type DP-transfected cells (WT), and - indicates
that recognition is statistically indistinguishable from the cells
transfected with only the tk gene (Ltk+). The data for mutant
DP20(Y27N) is provided in detail (see text and Figs. 4 and 5). NT, not
tested.
Genetics: Murray et al.
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FIG. 4. Cell-surface RIA of L cells transfected with the wild-type
H-2DP gene.(WT), the DP20(Y27N) mutant gene, or the tk gene alone
(Ltk+). (A) Binding with mAb 7-16.10. (B) Binding with mAb 135. (C)
Binding with miiAb 11-20.3. All these antibodies have been described
(21, 22). Values are the mean value of triplicate samples and are
expressed as cpm x lo-.
wild-type transfected cells and cells expressing mutant mol-
ecules. This serves as an important control of antigen density
when comparing recognition by CTLs.
Recognition by H-2-Restricted CTLs. We tested spleen cells
from LCMV-infected B1O.P mice for their ability to lyse
LCMV-infected L cells expressing the mutant molecules,
wild-type H-2DP molecules, or just the tk gene. (BlO.P mice
express and use the wild-type DP molecule as an LCMV-
restriction element). L cells expressing the wild-type DP
molecule were lysed, but only if cells were infected with
LCMV. The L-cell line expressing only the tk gene was not
lysed, regardless of LCMV infection. LCMV-infected DP20-
(Y27N) targets are killed as efficiently as LCMV-infected
cells expressing the wild-type DP molecule (Fig. SA). The
other mutants listed in Table 1 were also killed at levels
indistinguishable from wild-type transfected cells. If cells
were not infected by LCMV, they were not killed (data not
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FIG. 5. Killing of L cells transfected with mutant gene DP20-
(Y27N). (A) Killing of LCMV-infected L cells transfected with the
wild-type gene (o), with DP20(Y27N) mutant gene (A), or with the tk
gene alone (o). Effectors were prepared from B1O.P mice infected
with 105 plaque-forming units of Armstrong strain LCMV for 6 days.
(B) Killing of L cells transfected with the wild-type H-2DP gene (e),
with the DP2O(Y27N) mutant gene (A), or with the tk gene alone (o)
by B1O.P-specific alloreactive CTLs.
tion element indistinguishable from the wild-type product by
polyclonal CTLs specific for wild-type DP and LCMV.
Ailospecific Recognition of DP Depends on Tyrosine-27. To
examine allorecognition of the mutant molecules, we pre-
pared B10.P-specific CTLs from C3H mice. As seen in Fig.
SB, L cells expressing the wild-type molecule were recog-
nized and killed by the C3H effector cells. In contrast, the
mutant DP20(Y27N) was not recognized by the same popu-
lation of allospecific CTLs. L cells transfected with only the
tk gene were not killed. Thus we conclude that tyrosine-27 is
a critical residue for allorecognition of H-2DP by polyclonal
DP-specific C3H CTLs. However, the same mutation does
not affect self-recognition of LCMV-infected cells. We have
repeated this same experiment by using alloreactive C3H
CTLs and DP20(Y27N) targets three separate times and
obtained identical results.
DISCUSSION
We have shown that the technique of saturation mutagenesis
can be applied to the gene for a large intact eukaryotic protein
domain. Our experiments have produced a stable library of
point mutations not obtainable by conventional mutagenesis
methods. This allows us to sample mutations for polymorphic
and conserved amino acid residues. Once significant epitopes
for CTL recognition are identified, such as tyrosine-27,
additional mutations in this region, either from our library or
created by site-directed mutagenesis, can further define this
structure in greater detail. It is important to note that prior
information did not implicate tyrosine-27 as a critical residue
and we believe that this emphasizes how the unbiased
mutagenesis described can provide unexpected phenotypic
information.
We believe the tyrosine-27 to asparagine mutation is par-
ticularly interesting. The C3H CTL population, allospecific for
wild-type DP that does not recognize DP20(Y27N), is polyclo-
nal. Such populations are likely to contain a variety of CTLs
that recognize at least partially different epitopes on the same
DP molecule. Therefore, it was not surprising that most of the
assays for these mutant molecules were comparable to wild-
type levels. If one of several epitopes was altered by a
mutation, then recognition could still occur that resulted in
target cell lysis. This serves to further emphasize the extreme
nature of the DP20(Y27N) mutation that affects at least the
majority of the allospecific C3H CTLs. Since DP20(Y27N) is
not recognized by alloreactive CTLs and is indistinguishable
from L cells not transfected with DP, we believe we have
identified a residue critical for allorecognition.
The three-dimensional structure of the HLA.A2 molecule
(25, 27) has allowed us to localize the amino acid replace-
ments used in this study. Assuming the overall class I
molecular structure is conserved between mouse and human,
tyrosine-27 is at the endpoint of the second al f3 strand. This
location is on the floor of the putative peptide-binding pocket
and forms contacts with amino acids located in the a3 protein
domain and with f32-microglobulin. Preliminary experiments
suggest that the mutant molecule is associated with 182-
microglobulin at the cell surface, ruling out the possibility
that a grossly altered interaction between the heavy and light
chain of this molecule is the cause of the mutant phenotype
(J. Alexander, R.M., J.A.F., and P. Cresswell, unpublished
observations). We reason that, due to the placement of this
residue and its predicted amino acid contacts, we have not
directly affected a contact point with the T-cell receptor. The
mutation tyrosine-27 to asparagine may have induced a
change in the presentation of polymorphic residues or in-
duced a change in the capacity to bind proposed processed
self-peptides (28). The interaction with the a3 domain implies
a similarity with the a3 mutant described by Potter et al. (29)
that also disrupts allo CTL recognition. It is useful to
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sumably the product of a gene conversion event that changes
polymorphic residues at positions 22, 23, and 24 on the same
,B strand as tyrosine-27. The Kbms molecule is, by definition,
altered in allorecognition and does in fact present LCMV
antigens to CTLs, albeit at a reduced efficiency (30).
The other phenotypically silent mutants characterized here
can also be interpreted in light of the HLA.A2 structure.
DP164(R14L) is in a loop outside the obvious contact regions,
as is DP181(D37H). DP174(P57Q) and DP14(AllV;E32Q) are
more difficult to understand. A11V is a conservative substi-
tution under the al a-helix that might easily be silent.
However, E32Q, in the same molecule, is a nonconservative
substitution at the start of the third P-strand but does not alter
recognition at the polyclonal level. The mutation in DP174-
(P57Q) occurs, at first glance, at an interesting position. The
proline at residue 57 is predicted to break the al a-helix. The
substitution at this position has not produced an alteration
that we have detected but, due to the position of this residue,
it may warrant further investigation.
Tyrosine-27 is conserved in all MHC class I sequences
determined to date (human, mouse, and rabbit) (31). It has
been suggested that accessory molecules of the T-cell recep-
tor complex are critical in maintaining an efficient interaction
with an MHC ligand. Specifically, the conserved nature of
CD8 molecules (Lyt-2 in this case) has led to the suggestion
that CD8 stabilizes T-cell-target-cell interaction by binding to
conserved portions of the MHC recognition structures (32).
Therefore, it is possible that we have disrupted a stabilizing
interaction of the Lyt-2 molecule and the DP target structure
by the mutation at the conserved tyrosine-27 residue. How-
ever, in light of the placement of the tyrosine-27 residue on
the class I structure, it is unlikely that we have directly
affected an Lyt-2-DP interaction.
To raise another point related to the mutation at the
conserved tyrosine-27 residue, we believe this mutant is a
noteworthy example of the usefulness of this mutagenesis
technique, as it probably would not have been isolated by
other conventional mutagenesis methods. Cells with other
class I mutations affecting antibody recognition have been
isolated by negative selection by using a specific mAb and
complement. These mutations occur in polymorphic portions
of the gene (33-35). We have clearly shown that the epitopes
for three noncompeting mAb are not disrupted by the
mutation in DP20(Y27N). Therefore, negative selection with
our mAb and complement would have excluded the DP20-
(Y27N) mutant. The naturally occurring Kb mutants are
thought to have arisen by gene conversion events (30)
through changes at polymorphic but not conserved residues.
Therefore, mutations in conserved residues, such as tyro-
sine-27, could not be recovered among the mutants generated
in vivo. Also, a completely conserved residue would not have
been an immediate choice for site-directed mutagenesis, a
technique proven effective if a residue is thought to be critical
by other criteria (36-38). Thus we believe this mutagenesis
technique is exceptionally useful to rapidly produce a wide
spectrum of unbiased mutants and is a powerful tool for
structure-function analysis and protein designing studies.
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